INNTEROX Business Case

Mohamed Ragab Abdel Alim - Marketing

Marketing Management > Segmentation , Targeting & Positioning

The presentation slide titled "INNTEROX Business Case" provides a crucial Market Summary for the Chronic and acute pain and inflammation (M01A NSAIDs) segment, analyzing the market size at 100 Million Units and 2.942 Billion Units in value for the 2023-2024 timeframe. The treatment landscape involves various pharmacological options, including Traditional NSAIDs (like Diclofenac and Ibuprofen), Selective COX-2 Inhibitors, and Opioid Analgesics, alongside non-pharmacological therapies. The key prescribers are specialists and Primary Care Physicians, while current prescribing habits are governed by the primary goal of pain relief, highlighting that physicians view NSAIDs as efficacious and cost-effective but are concerned with their side effects, with Diclofenac noted as the most widely used class.